Sanofi SA (SNY) Shares Bought by Advisor Partners LLC
Advisor Partners LLC increased its stake in Sanofi SA (NYSE:SNY) by 51.4% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 9,846 shares of the company’s stock after buying an additional 3,343 shares during the quarter. Advisor Partners LLC’s holdings in Sanofi were worth $440,000 at the end of the most recent reporting period.
A number of other hedge funds also recently bought and sold shares of the stock. Huntington National Bank lifted its holdings in Sanofi by 24.9% in the second quarter. Huntington National Bank now owns 6,037 shares of the company’s stock worth $242,000 after purchasing an additional 1,202 shares during the period. Wealthstreet Investment Advisors LLC lifted its holdings in Sanofi by 14.3% in the third quarter. Wealthstreet Investment Advisors LLC now owns 10,392 shares of the company’s stock worth $464,000 after purchasing an additional 1,300 shares during the period. Pekin Singer Strauss Asset Management IL lifted its holdings in Sanofi by 3.6% in the second quarter. Pekin Singer Strauss Asset Management IL now owns 38,355 shares of the company’s stock worth $1,535,000 after purchasing an additional 1,315 shares during the period. Steward Partners Investment Advisory LLC lifted its holdings in Sanofi by 8.3% in the second quarter. Steward Partners Investment Advisory LLC now owns 18,344 shares of the company’s stock worth $734,000 after purchasing an additional 1,401 shares during the period. Finally, Zions Bancorporation lifted its holdings in Sanofi by 8.7% in the second quarter. Zions Bancorporation now owns 19,340 shares of the company’s stock worth $774,000 after purchasing an additional 1,544 shares during the period. 7.47% of the stock is owned by institutional investors and hedge funds.
Shares of NYSE SNY opened at $44.90 on Wednesday. Sanofi SA has a twelve month low of $37.43 and a twelve month high of $46.25. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.22 and a quick ratio of 0.85. The stock has a market capitalization of $114.34 billion, a price-to-earnings ratio of 14.35, a price-to-earnings-growth ratio of 2.58 and a beta of 0.70.
SNY has been the subject of a number of research analyst reports. Citigroup raised shares of Sanofi from a “neutral” rating to a “buy” rating in a report on Friday, August 10th. Bank of America raised shares of Sanofi from a “neutral” rating to a “buy” rating and set a $55.00 price target for the company in a report on Monday, September 10th. Zacks Investment Research raised shares of Sanofi from a “sell” rating to a “hold” rating in a report on Tuesday, September 11th. Argus upped their price target on shares of Sanofi from $46.00 to $48.00 and gave the company a “buy” rating in a report on Friday, August 24th. Finally, JPMorgan Chase & Co. reissued a “neutral” rating on shares of Sanofi in a report on Tuesday, July 31st. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and six have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $49.50.
In other Sanofi news, major shareholder Sanofi sold 104,552 shares of the business’s stock in a transaction dated Thursday, September 6th. The stock was sold at an average price of $406.68, for a total transaction of $42,519,207.36. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 1.00% of the stock is currently owned by insiders.
COPYRIGHT VIOLATION NOTICE: “Sanofi SA (SNY) Shares Bought by Advisor Partners LLC” was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this report on another domain, it was copied illegally and republished in violation of U.S. & international trademark & copyright laws. The correct version of this report can be read at https://www.thecerbatgem.com/2018/11/14/sanofi-sa-sny-shares-bought-by-advisor-partners-llc.html.
Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an oral immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.
Read More: Inflation
Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi SA (NYSE:SNY).
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.